Eli Lilly has been outperforming for many months: Alissa Coram
Alissa Coram, executive editor at Investor's Business Daily, discusses the performance of Eli Lilly, stating that it has been outperforming in the stock market over a significant period. She raises the question of whether the overall stock market, which is currently experiencing a downturn, may be due for an upward bounce.
Stock Forecasts
LLY
Positive
Eli Lilly's continued strong performance suggests it has a competitive advantage in the pharmaceutical sector, particularly with its recent product launches and innovations. The mention of a possible bounce in the stock market could further bolster investor sentiment toward strong performers like Eli Lilly.
Related News
Weight-loss drug competition heats up with growing pill market
Sep 17, 2024, 5:32 PM
GLP-1 pills are the next frontier for the weight-loss market.
Investor's Business Daily executive editor Alissa Coram discusses whether the 'down' stock market is due for a bounce this week on 'Varney & Co.'
Why Big Pharma is betting on telehealth strategies
Sep 6, 2024, 4:52 PM
The telehealth world is entering a new phase of vertical integration in healthcare.